Abstract

The current treatment options for inflammatory bowel disease (IBD) are unsatisfactory. Therefore, novel and safer therapies are needed. We previously reported that koreanaside A (KA) showed high radical scavenging activity and suppressed vascular cell adhesion molecule 1 (VCAM-1) expression in vascular smooth muscle cells. However, the molecular mechanisms involved in its anti-inflammatory effect have not been reported. KA inhibited pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), nitric oxide (NO), and prostaglandin E2 (PGE2). KA inhibited the production and mRNA expression of interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) induced by LPS. KA downregulated the myeloid differentiation primary response 88 (MyD88)-dependent inflammatory gene expressions in the MyD88-overexpressed cells. KA suppressed the LPS-induced transcriptional and DNA-binding activities of activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB). KA was found to inhibit the phosphorylation of Janus kinase 1/2 (JAK1/2) and signal transducers and activators of transcription 1/3 (STAT1/3). In DSS-induced colitis mice, KA relieved the symptoms of colitis by suppressing inflammatory cell infiltration, restoring tight junction (TJ)- and epithelial–mesenchymal transition (EMT)-related protein expression, and inactivating AP-1, NF-κB, and STAT1/3. Therefore, KA reduced inflammatory responses by downregulating AP-1, NF-κB, and JAK/STAT signaling in LPS-induced macrophages and DSS-induced colitis mice.

Highlights

  • Inflammatory bowel disease (IBD) commonly manifests in the form of Crohn’s disease and ulcerative colitis

  • On nitric oxide (NO) and prostaglandin E2 (PGE2) production were not caused by its nonspecific cytotoxicity, because koreanaside A (KA) had no effect on cell viability, as determined by MTT assay up to 80 μM

  • To determine whether the inhibitory effects of KA on NO and PGE2 production are related to inducible nitric oxide synthase and cyclooxygenase-2 (COX-2) expression, we evaluated iNOS and COX-2 protein and mRNA

Read more

Summary

Introduction

Inflammatory bowel disease (IBD) commonly manifests in the form of Crohn’s disease and ulcerative colitis. The pathogenesis of IBD may be characterized by a loss of intestinal epithelial integrity and a dysregulated immune system [1,2]. The intestinal tight junction (TJ) is composed of several proteins including transmembrane proteins such as zona occludens (ZO)-1, occludin, claudins, and junctional adhesion molecule (JAM). These proteins may play a key role in epithelial barrier regulation [3]. Several studies have reported that the disruption of the physiological conditions of the TJ and EMT network can contribute to the pathogenesis of ulcerative colitis and alter intestinal permeability in IBD. Pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interferon gamma (IFN-γ), interleukin (IL)-6, IL-12, IL-17, and anti-inflammatory cytokines such as IL-4, IL-10, and transforming growth factor-beta (TGF-β) play an important role in the regulation of inflammation [7,8]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.